Standout Papers

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for adv... 2021 2026 2022 2024188
  1. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆ (2021)
    Jiaxin Niu, Corinne Maurice‐Dror et al. Annals of Oncology

Immediate Impact

2 by Nobel laureates 61 standout
Sub-graph 1 of 23

Citing Papers

The interaction of innate immune and adaptive immune system
2024 Standout
The present and future of bispecific antibodies for cancer therapy
2024 Standout
2 intermediate papers

Works of D.H. Lee being referenced

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆
2021 Standout
1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC
2020

Author Peers

Author Last Decade Papers Cites
D.H. Lee 253 110 26 142 16 369
Nausicaa Malissen 191 126 30 72 25 340
Edwin A. Basak 308 90 43 119 18 384
Esmée P. Hoefsmit 182 92 30 119 14 339
George Mo 158 48 12 79 17 318
R. Mondéjar 211 65 21 50 23 364
Aroop Mangalik 228 135 16 45 13 392
Andrea D. Chapman 164 174 26 81 20 359
Jean-François Emile 126 143 19 110 11 348
Yuji Hirami 217 160 20 142 21 395
Konstantinos Rounis 216 96 20 42 22 324

All Works

Loading papers...

Rankless by CCL
2026